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Background
We continue to make progress on a multi-epitope, cross-
clade GAIA HIV vaccine [De Groot, Vaccine, 2008, 26:
3059–71]. New evidence from elite controllers supports
our original hypothesis that multiple, highly conserved T-
cell epitopes in a single HIV vaccine construct will better
control HIV infection [Davenport, Immunol Rev., April
2007; Kong, J Virol., March 2009]. We believe that T cell-
mediated vaccines constructed from highly cross-con-
served HIV Th and CTL epitopes will succeed with the
benefit of advances in the adjuvant, formulation and
delivery areas that will inform better vaccine construction.
We have performed several recent studies that also sup-
port this hypothesis.
Methods
EpiVax' suite of vaccine design tools have enabled effec-
tive selection of cross-clade conserved HIV epitopes, and
the delivery of those epitopes in properly designed con-
structs are important steps toward production of an effec-
tive vaccine.
Results
We provide three recent T-cell directed vaccination suc-
cesses that illustrate the use of such vaccine design tools in
preclinical challenge models and their potential for devel-
opment of a protective T cell-directed HIV vaccine: (i)
HLA class II conserved T-cell epitopes derived from the
variola genome fully protected HLA DR3 transgenic mice
from 10× LD50 vaccinia challenge without B cell priming;
(ii) HLA class I and class II F. tularensis T-cell epitopes
extended the mean time-to-death of A2/DR1 transgenic
mice challenged with 20× LD50 attenuated F. holarctica
by 53%; and, (iii) HLA class II T-cell epitopes stimulated
long-lived immune responses and cleared infection in a
p27 knockout mouse model of H. pylori infection.
Conclusion
The lessons learned from these recent studies hold prom-
ise for design of a globally relevant HIV vaccine using
cross-clade HLA class I and class II T-cell epitopes, con-
served over time and geography, that will be broadly
immunogenic in the HLA diverse world population.
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